NCT01365533View on ClinicalTrials.gov

A Study to Evaluate the Effect of Roflumilast on Airway Inflammation and Function Following Allergen Challenge in Subjects With Allergic Asthma

PHASE2CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

December 31, 2004

Primary Completion Date

July 31, 2005

Study Completion Date

July 31, 2005

Conditions
Allergic Asthma
Interventions
DRUG

Roflumilast

Roflumilast 500 μg, one tablet once daily, orally

DRUG

Placebo

Placebo, one tablet once daily, orally

Trial Locations (1)

Unknown

Nycomed investigational site, Québec

Sponsors

Lead Sponsor

AstraZeneca
All Listed Sponsors
lead

AstraZeneca

INDUSTRY